Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding

J Thorac Oncol. 2018 Dec;13(12):e247-e248. doi: 10.1016/j.jtho.2018.07.013.

Authors

Filippo Gustavo Dall'Olio¹, Francesca Sperandi¹, Karim Rihawi¹, Mauro Gargiulo², Barbara Melotti¹, Stefano Brocchi³, Francesco Gelsomino⁴, Andrea Ardizzoni¹

Affiliations

¹ Division of Oncology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
² Division of Vascular Surgery, University of Bologna, DIMES, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
³ Radiology Unit, Department of Diagnostic Medicine and Prevention, S. Orsola-Malpighi Hospital, Bologna, Italy.
⁴ Division of Oncology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. Electronic address: [email protected].

PMID: 30467045
DOI: 10.1016/j.jtho.2018.07.013

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Arterial Occlusive Diseases / chemically induced*
Arterial Occlusive Diseases / diagnosis
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / secondary
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Nivolumab / adverse effects*
Prognosis
Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab